RT Journal Article
T1 Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective
A1 López-Méndez, Tania B.
A1 Sánchez-Álvarez, Miguel
A1 Trionfetti, Flavia
A1 Pedraz, José L.
A1 Tripodi, Marco
A1 Cordani, Marco
A1 Strippoli, Raffaele
A1 González-Valdivieso, Juan
AB In recent years, progress in nanotechnology provided new tools to treat cancer more effectively. Advances in biomaterials tailored for drug delivery have the potential to overcome the limited selectivity and side effects frequently associated with traditional therapeutic agents. While autophagy is pivotal in determining cell fate and adaptation to different challenges, and despite the fact that it is frequently dysregulated in cancer, antitumor therapeutic strategies leveraging on or targeting this process are scarce. This is due to many reasons, including the very contextual effects of autophagy in cancer, low bioavailability and non-targeted delivery of existing autophagy modulatory compounds. Conjugating the versatile characteristics of nanoparticles with autophagy modulators may render these drugs safer and more effective for cancer treatment. Here, we review current standing questions on the biology of autophagy in tumor progression, and precursory studies and the state-of-the-art in harnessing nanomaterials science to enhance the specificity and therapeutic potential of autophagy modulators.
PB Springer Nature
SN 2045-3701
YR 2023
FD 2023-03-04
LK https://hdl.handle.net/20.500.14352/73050
UL https://hdl.handle.net/20.500.14352/73050
LA eng
NO López-Méndez, T.B., Sánchez-Álvarez, M., Trionfetti, F. et al. Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective. Cell Biosci 13, 44 (2023). https://doi.org/10.1186/s13578-023-00986-9
NO Ministerio de Ciencia, Innovación y Universidades (España)
NO Universidad Complutense de Madrid
NO Ministro dell'Istruzione e del Merito (Italia)
NO Ministero della Salute (Italia)
DS Docta Complutense
RD 8 abr 2025